Phase 1 Breast Clinical Trials
376 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 376 trials
Recruiting
Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Breast CancerPancreatic CancerOvarian Cancer+2 more
National Cancer Institute (NCI)124 enrolled1 locationNCT02830724
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled45 locationsNCT07100106
Recruiting
Phase 1
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 1
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588
Recruiting
Phase 1
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Breast CancerColorectal, CancerEsophageal Cancer+3 more
Immunome, Inc.175 enrolled1 locationNCT07578571
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled17 locationsNCT05768932
Recruiting
Phase 1
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow23 enrolled1 locationNCT04997993
Recruiting
Phase 1Phase 2
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.80 enrolled1 locationNCT06974929
Recruiting
Phase 1
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 1
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Breast CancerGastric CancerCervical Cancer+1 more
Christian Hinrichs30 enrolled2 locationsNCT05483491
Recruiting
Phase 1
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
Breast Cancer
Atridia Pty Ltd.15 enrolled3 locationsNCT07358377
Recruiting
Phase 1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 1
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)32 enrolled10 locationsNCT05673200
Recruiting
Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Triple-Negative Breast CancerPancreatic CancerMelanoma+7 more
Memgen, Inc.40 enrolled2 locationsNCT05076760
Recruiting
Phase 1
THE-0504 in Patients With Solid Tumors
Triple-Negative Breast CancerGastric Cancer (GC)Small Cell Lung Cancer ( SCLC )+2 more
Thena Biotech S.r.l.30 enrolled1 locationNCT07646106